351 related articles for article (PubMed ID: 32958250)
1. Potent antiviral effect of silver nanoparticles on SARS-CoV-2.
Jeremiah SS; Miyakawa K; Morita T; Yamaoka Y; Ryo A
Biochem Biophys Res Commun; 2020 Nov; 533(1):195-200. PubMed ID: 32958250
[TBL] [Abstract][Full Text] [Related]
2. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
3. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
4. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
[TBL] [Abstract][Full Text] [Related]
6. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Jeon S; Ko M; Lee J; Choi I; Byun SY; Park S; Shum D; Kim S
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366720
[TBL] [Abstract][Full Text] [Related]
7. Cationic drugs and COVID-19.
Brenna OV; Torretta S; Pignataro L; Di Berardino F
Int J Immunopathol Pharmacol; 2020; 34():2058738420966078. PubMed ID: 33045858
[TBL] [Abstract][Full Text] [Related]
8. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
9. Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2.
Meister TL; Brüggemann Y; Todt D; Conzelmann C; Müller JA; Groß R; Münch J; Krawczyk A; Steinmann J; Steinmann J; Pfaender S; Steinmann E
J Infect Dis; 2020 Sep; 222(8):1289-1292. PubMed ID: 32726430
[TBL] [Abstract][Full Text] [Related]
10. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
[TBL] [Abstract][Full Text] [Related]
11. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
12. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
13. Lithium for the 2019 novel coronavirus.
Gómez-Bernal G
Med Hypotheses; 2020 Sep; 142():109822. PubMed ID: 32408073
[No Abstract] [Full Text] [Related]
14. SARS-CoV-2 and the safety margins of cell-based biological medicinal products.
Modrof J; Kerschbaum A; Farcet MR; Niemeyer D; Corman VM; Kreil TR
Biologicals; 2020 Nov; 68():122-124. PubMed ID: 32891497
[TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine as a potential treatment for COVID-19.
Jorge-Aarón RM; Rosa-Ester MP
Future Microbiol; 2020 Jul; 15():959-962. PubMed ID: 32662664
[No Abstract] [Full Text] [Related]
16. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Ma Q; Li R; Pan W; Huang W; Liu B; Xie Y; Wang Z; Li C; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Hui M; Fu L; Yang Z
Phytomedicine; 2020 Nov; 78():153296. PubMed ID: 32890913
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM
EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968
[TBL] [Abstract][Full Text] [Related]
18. Imatinib is not a potent anti-SARS-CoV-2 drug.
Zhao H; Mendenhall M; Deininger MW
Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
[No Abstract] [Full Text] [Related]
19. Lactoferrin as potential preventative and adjunct treatment for COVID-19.
Chang R; Ng TB; Sun WZ
Int J Antimicrob Agents; 2020 Sep; 56(3):106118. PubMed ID: 32738305
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Nau JY
Rev Med Suisse; 2020 Mar; 16(685):510-511. PubMed ID: 32167254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
